Egetis Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-374.6	-342.1	-343.2	-326.8	-193.8	-104.5
Other Adjustments	63.4	49.1	27	17.7	9.4	2.7
Change in Receivables	12.7	-8.6	13.4	-22.9	-10.7	3.1
Changes in Accounts Payable	33.6	35	75.2	53.8	21.6	-31.3
Operating Cash Flow	-265.2	-267	-227.9	-278.4	-173.5	-130.1
Capital Expenditures	-1.2	-1.5	-	0	-	-0.2
Purchases of Investments	-	-	-	-	0	-0.8
Payments for Business Acquisitions	-1.3	-1.3	-1.2	-	-1.7	-5
Investing Cash Flow	-2.4	-2.8	-1.2	0	-1.7	-6
Long-Term Debt Issued	-	-	-	108.8	-	-
Long-Term Debt Repaid	-29.7	-29.3	-7.7	-3	-7.5	-7.5
Net Long-Term Debt Issued (Repaid)	-29.7	-29.3	-7.7	105.8	-7.5	-7.5
Issuance of Common Stock	183.2	183.2	301.5	381.9	177.4	-
Repurchase of Common Stock	-	-	-1.5	-	-	-
Net Common Stock Issued (Repurchased)	183.2	183.2	300	381.9	177.4	-
Other Financing Activities	-14.1	-13.9	-21.3	-28.9	-14.2	-1.4
Financing Cash Flow	139.4	140	270.9	458.9	155.7	-8.9
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-2	-5.4	5.8	-4.8	3.2	1.1
Net Cash Flow	-128.2	-129.8	41.8	180.4	-19.5	-145
Free Cash Flow	-266.4	-268.5	-227.9	-278.4	-173.5	-130.3
FCF Margin	-422.19%	-430.29%	-494.36%	-483.33%	-767.70%	-341.10%
Free Cash Flow Per Share	-0.70	-0.72	-0.73	-1.07	-0.89	-0.72
Levered Free Cash Flow	-277	-338.3	-276.1	-167.3	-179.7	-143.5
Unlevered Free Cash Flow	-335.41	-306	-253.91	-270.9	-176.5	-137.2